醫彙集團(08161.HK)盈喜:預期年度税前溢利不多於810萬港元
格隆匯6月16日丨醫彙集團(08161.HK)公吿,根據董事會現時可得資料以及對集團截至2025年3月31日止年度未經審核綜合管理賬目作出的初步審閲及評估,預期集團於報吿期內可能錄得除税前溢利不多於810萬港元,而於截至2024年3月31日止年度則錄得除税前虧損約800萬港元。
上述改善乃主要由於經考慮代價的公平值後出售一間附屬公司的收益約1280萬港元以及有效實施成本控制措施令醫療及牙科供應品成本大幅減少約350萬港元所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.